The DOI matches its Crossref record; 194 of the 194 references it cites were found in a registry or an index.
The Discovery and Development of Selective Estrogen Receptor Modulators (SERMs) for Clinical Practice
Open accessAbstract
Selective estrogen receptor modulators (SERMs) are structurally different compounds that interact with intracellular estrogen receptors in target organs as estrogen receptor agonists or antagonists. These drugs have been intensively studied over the past decade and have proven to be a highly versatile group for the treatment of different conditions associated with postmenopausal women's health, including hormone responsive cancer and osteoporosis. Tamoxifen, a failed contraceptive is currently used to treat all stages of breast cancer, chemoprevention in women at high risk for breast cancer and also has beneficial effects on bone mineral density and serum lipids in postmenopausal women. Raloxifene, a failed breast cancer drug, is the only SERM approved internationally for the prevention and treatment of postmenopausal osteoporosis and vertebral fractures. However, although these SERMs have many benefits, they also have some potentially serious adverse effects, such as thromboembolic disorders and, in the case of tamoxifen, uterine cancer. These adverse effects represent a major concern given that long-term therapy is required to prevent osteoporosis or prevent and treat breast cancer. The search for the 'ideal' SERM, which would have estrogenic effects on bone and serum lipids, neutral effects on the uterus, and antiestrogenic effects on breast tissue, but none of the adverse effects associated with current therapies, is currently under way. Ospemifene, lasofoxifene, bazedoxifene and arzoxifene, which are new SERM molecules with potentially greater efficacy and potency than previous SERMs, have been investigated for use in the treatment and prevention of osteoporosis. These drugs have been shown to be comparably effective to conventional hormone replacement therapy in animal models, with potential indications for an improved safety profile. Clinical efficacy data from ongoing phase III trials are available or are awaited for each SERM so that a true understanding of the therapeutic potential of these compounds can be obtained. In this article, we describe the discovery and development of the group of medicines called SERMs. The newer SERMs in late development: ospemifene, lasofoxifene, bazedoxifene, are arzoxifene are described in detail.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M., Cronin, W. M., Vogel, V., Robidoux, A., Dimitrov, N., Atkins, J., et al. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.18.1371 · Cited by 5,485
Cloning of a novel receptor expressed in rat prostate and ovary.
Kuiper, G. G., Enmark, E., Pelto-Huikko, M., Nilsson, S., & Gustafsson, J. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.12.5925 · Cited by 4,788
Kuiper, G. G. J. M., Carlsson, B., Grandien, K., Enmark, E., Häggblad, J., Nilsson, S., & Gustafsson, J.-A. (1997) · Endocrinology · doi:10.1210/endo.138.3.4979 · Cited by 4,442
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Molecular basis of agonism and antagonism in the oestrogen receptor
Brzozowski, A. M., Pike, A. C. W., Dauter, Z., Hubbard, R. E., Bonn, T., Engström, O., Öhman, L., Greene, G. L., Gustafsson, J.-Å., & Carlquist, M. (1997) · Nature · doi:10.1038/39645 · Cited by 3,355
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2011) · The Lancet · doi:10.1016/s0140-6736(11)60993-8 · Cited by 3,075
Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Black, D. M., Delmas, P. D., Eastell, R., Reid, I. R., Boonen, S., Cauley, J. A., Cosman, F., Lakatos, P., Leung, P. C., Man, Z., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067312 · Cited by 2,986
Shiau, A. K., Barstad, D., Loria, P. M., Cheng, L., Kushner, P. J., Agard, D. A., & Greene, G. L. (1998) · Cell · doi:10.1016/s0092-8674(00)81717-1 · Cited by 2,729
Sequence and Characterization of a Coactivator for the Steroid Hormone Receptor Superfamily
Oñate, S. A., Tsai, S. Y., Tsai, M.-J., & O'Malley, B. W. (1995) · Science · doi:10.1126/science.270.5240.1354 · Cited by 2,387
Cummings, S. R., Eckert, S., Krueger, K. A., Grady, D., Powles, T. J., Cauley, J. A., Norton, L., Nickelsen, T., Bjarnason, N. H., Morrow, M., et al. (1999) · JAMA · doi:10.1001/jama.281.23.2189 · Cited by 1,872
Differential Ligand Activation of Estrogen Receptors ERα and ERβ at AP1 Sites
Paech, K., Webb, P., Kuiper, G. G. J. M., Nilsson, S., Gustafsson, J.-Å., Kushner, P. J., & Scanlan, T. S. (1997) · Science · doi:10.1126/science.277.5331.1508 · Cited by 1,861
Cofactor Dynamics and Sufficiency in Estrogen Receptor–Regulated Transcription
Shang, Y., Hu, X., DiRenzo, J., Lazar, M. A., & Brown, M. (2000) · Cell · doi:10.1016/s0092-8674(00)00188-4 · Cited by 1,657
Fisher, B., Costantino, J. P., Wickerham, D. L., Cecchini, R. S., Cronin, W. M., Robidoux, A., Bevers, T. B., Kavanah, M. T., Atkins, J. N., Margolese, R. G., et al. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji372 · Cited by 1,339
Sequence and Expression of Human Estrogen Receptor Complementary DNA
Greene, G. L., Gilna, P., Waterfield, M., Baker, A., Hort, Y., & Shine, J. (1986) · Science · doi:10.1126/science.3753802 · Cited by 1,311
Effect of Statins on Risk of Coronary Disease: A Meta-analysis of Randomized Controlled Trials
LaRosa, J. C., He, J., & Vupputuri, S. (1999) · JAMA · doi:10.1001/jama.282.24.2340 · Cited by 1,246
Comprehensive medicinal chemistry
Timmerman, H., Bast, A., Van der Goot, H., Vermeulen, N. P. E., & Zeelen, F. J. (1991) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(91)90535-z · Cited by 1,163
Shou, J., Massarweh, S., Osborne, C. K., Wakeling, A. E., Ali, S., Weiss, H., & Schiff, R. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh166 · Cited by 1,153
Effects of Tamoxifen on Bone Mineral Density in Postmenopausal Women with Breast Cancer
Love, R. R., Mazess, R. B., Barden, H. S., Epstein, S., Newcomb, P. A., Jordan, V. C., Carbone, P. P., & DeMets, D. L. (1992) · New England Journal of Medicine · doi:10.1056/nejm199203263261302 · Cited by 1,129
Hall, J. M., & McDonnell, D. P. (1999) · Endocrinology · doi:10.1210/endo.140.12.7179 · Cited by 1,075
Effects of Raloxifene on Cardiovascular Events and Breast Cancer in Postmenopausal Women
Barrett-Connor, E., Mosca, L., Collins, P., Geiger, M. J., Grady, D., Kornitzer, M., McNabb, M. A., & Wenger, N. K. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062462 · Cited by 1,048
Exemestane for Breast-Cancer Prevention in Postmenopausal Women
Goss, P. E., Ingle, J. N., Alés-Martínez, J. E., Cheung, A. M., Chlebowski, R. T., Wactawski-Wende, J., McTiernan, A., Robbins, J., Johnson, K. C., Martin, L. W., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103507 · Cited by 970
Jin, Y., Desta, Z., Stearns, V., Ward, B., Ho, H., Lee, K.-H., Skaar, T., Storniolo, A. M., Li, L., Araba, A., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji005 · Cited by 951
Coregulator Function: A Key to Understanding Tissue Specificity of Selective Receptor Modulators
Smith, C. L., & O’Malley, B. W. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0023 · Cited by 931
ADJUVANT TAMOXIFEN IN EARLY BREAST CANCER: OCCURRENCE OF NEW PRIMARY CANCERS
Fornander, T., Cedermark, B., Mattsson, A., Skoog, L., Theve, T., Askergren, J., Rutqvist, L., Glas, U., Silfverswärd, C., Somell, A., et al. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91141-0 · Cited by 920
Stearns, V. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg108 · Cited by 850
Tamoxifen: a most unlikely pioneering medicine
Jordan, V. C. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1031 · Cited by 824
Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen
Dowsett, M., Cuzick, J., Ingle, J., Coates, A., Forbes, J., Bliss, J., Buyse, M., Baum, M., Buzdar, A., Colleoni, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.1274 · Cited by 813
Cummings, S. R. (1999) · Medical Entomology and Zoology · Cited by 797
Goetz, M. P., Rae, J. M., Suman, V. J., Safgren, S. L., Ames, M. M., Visscher, D. W., Reynolds, C., Couch, F. J., Lingle, W. L., Flockhart, D. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.3266 · Cited by 791
Osborne, C. K., Bardou, V., Hopp, T. A., Chamness, G. C., Hilsenbeck, S. G., Fuqua, S. A. W., Wong, J., Allred, D. C., Clark, G. M., & Schiff, R. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.5.353 · Cited by 786
Barkhem, T., Carlsson, B., Nilsson, Y., Enmark, E., Gustafsson, J.-Å., & Nilsson, S. (1998) · Molecular Pharmacology · doi:10.1124/mol.54.1.105 · Cited by 779
A New Anti-oestrogenic Agent in Late Breast Cancer: An Early Clinical Appraisal of ICI46474
Cole, M. P., Jones, C. T. A., & Todd, I. D. H. (1971) · British Journal of Cancer · doi:10.1038/bjc.1971.33 · Cited by 701
Martino, S., Cauley, J. A., Barrett-Connor, E., Powles, T. J., Mershon, J., Disch, D., Secrest, R. J., Cummings, S. R., & For the CORE Investigators (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh319 · Cited by 684
Vogel, V. G., Costantino, J. P., Wickerham, D. L., Cronin, W. M., Cecchini, R. S., Atkins, J. N., Bevers, T. B., Fehrenbacher, L., Pajon, E. R., Wade, J. L., et al. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0076 · Cited by 646
Black, L. J., Sato, M., Rowley, E. R., Magee, D. E., Bekele, A., Williams, D. C., Cullinan, G. J., Bendele, R., Kauffman, R. F., & Bensch, W. R. (1994) · Journal of Clinical Investigation · doi:10.1172/jci116985 · Cited by 609
Pols, H. A. P., Felsenberg, D., Hanley, D. A., Štepán, J., Muñoz-Torres, M., Wilkin, T. J., Qin-sheng, G., Galich, A. M., Vandormael, K., Yates, A. J., et al. (1999) · Osteoporosis International · doi:10.1007/pl00004171 · Cited by 593
Paruthiyil, S., Parmar, H., Kerekatte, V., Cunha, G. R., Firestone, G. L., & Leitman, D. C. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2446 · Cited by 576
Cuzick, J., Forbes, J. F., Sestak, I., Cawthorn, S., Hamed, H., Holli, K., & Howell, A. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk049 · Cited by 534
Silverman, S. L., Christiansen, C., Genant, H. K., Vukicevic, S., Zanchetta, J. R., de Villiers, T. J., Constantine, G. D., & Chines, A. A. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080710 · Cited by 508
A MONOHYDROXYLATED METABOLITE OF TAMOXIFEN WITH POTENT ANTIOESTROGENIC ACTIVITY
JORDAN, V. C., COLLINS, M. M., ROWSBY, L., & PRESTWICH, G. (1977) · Journal of Endocrinology · doi:10.1677/joe.0.0750305 · Cited by 506
BORGES, S., DESTA, Z., LI, L., SKAAR, T., WARD, B., NGUYEN, A., JIN, Y., STORNIOLO, A., NIKOLOFF, D., & WU, L. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.03.013 · Cited by 487
Nawrocki, J. W., Weiss, S. R., Davidson, M. H., Sprecher, D. L., Schwartz, S. L., Lupien, P.-J., Jones, P. H., Haber, H. E., & Black, D. M. (1995) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.15.5.678 · Cited by 484
Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors.
Roger, P., Sahla, M. E., Mäkelä, S., Gustafsson, J. A., Baldet, P., & Rochefort, H. (2001) · PubMed · Cited by 471
The Effects of Tibolone in Older Postmenopausal Women
Cummings, S. R., Ettinger, B., Delmas, P. D., Kenemans, P., Stathopoulos, V., Verweij, P., Mol-Arts, M., Kloosterboer, L., Mosca, L., Christiansen, C., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800743 · Cited by 457
Johnson, M. D., Zuo, H., Lee, K.-H., Trebley, J. P., Rae, J. M., Weatherman, R. V., Desta, Z., Flockhart, D. A., & Skaar, T. C. (2004) · Breast Cancer Research and Treatment · doi:10.1023/b:brea.0000025406.31193.e8 · Cited by 456
A NEW DERIVATIVE OF TRIPHENYLETHYLENE: EFFECT ON IMPLANTATION AND MODE OF ACTION IN RATS
HARPER, M. J. K., & WALPOLE, A. L. (1967) · Reproduction · doi:10.1530/jrf.0.0130101 · Cited by 445
Cholesterol Reduction Yields Clinical Benefit: Impact of Statin Trials
Gould, A. L., Rossouw, J. E., Santanello, N. C., Heyse, J. F., & Furberg, C. D. (1998) · Circulation · doi:10.1161/01.cir.97.10.946 · Cited by 442
Powles, T. J., Ashley, S., Tidy, A., Smith, I. E., & Dowsett, M. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk050 · Cited by 430
Wijayaratne, A. L., & McDonnell, D. P. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101097200 · Cited by 427
Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse.
Gottardis, M. M., Robinson, S. P., SATYASWAROOP, P. G., & Jordan, V. C. (1988) · PubMed · Cited by 422
Development of antiestrogens and their use in breast cancer: eighth Cain memorial award lecture.
Lerner, L. J., & Jordan, V. C. (1990) · PubMed · Cited by 417
Biochemical pharmacology of antiestrogen action.
Jordan, V. C. (1984) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06650-5 · Cited by 417
Jordan, V. C. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm020449y · Cited by 414
MCF-7: the first hormone-responsive breast cancer cell line.
Levenson, A. S., & Jordan, V. C. (1997) · PubMed · Cited by 410
Inverse, protean, and ligand‐selective agonism: matters of receptor conformation
KENAKIN, T. (2001) · The FASEB Journal · doi:10.1096/fj.00-0438rev · Cited by 408
Jordan, V. C. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm020450x · Cited by 396
Lasofoxifene in Postmenopausal Women with Osteoporosis
Cummings, S. R., Ensrud, K., Delmas, P. D., LaCroix, A. Z., Vukicevic, S., Reid, D. M., Goldstein, S., Sriram, U., Lee, A., Thompson, J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0808692 · Cited by 387
Anti-oestrogen Therapy for Breast Cancer: A Trial of Tamoxifen at Two Dose Levels
Ward, H. W. C. (1973) · BMJ · doi:10.1136/bmj.1.5844.13 · Cited by 375
Effects of Tamoxifen on Cardiovascular Risk Factors in Postmenopausal Women
Love, R. R., Wiebe, D. A., Newcomb, P. A., Cameron, L., Leventhal, H., Jordan, V. C., Feyzi, J., & DeMets, D. L. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-11-860 · Cited by 374
Estrogen Receptors: Therapies Targeted to Receptor Subtypes
Nilsson, S., & Gustafsson, J.-Å. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.226 · Cited by 370
Gottardis, M. M., & Jordan, V. C. (1987) · PubMed · Cited by 352
Induction of Ovulation with MRL/41: Preliminary Report
Greenblatt, R. B. (1961) · JAMA · doi:10.1001/jama.1961.03040410001001 · Cited by 343
Horwitz, K. B., & McGuire, W. L. (1978) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)34379-x · Cited by 341
Rutqvist, L. E., & Anders Mattsson for the Stockholm Breast Cancer Study Group (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.17.1398 · Cited by 334
Vogel, V. G., Costantino, J. P., Wickerham, D. L., Cronin, W. M., Cecchini, R. S., Atkins, J. N., Bevers, T. B., Fehrenbacher, L., Pajon, E. R., Wade, J. L., et al. (2006) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000238648.23538.42 · Cited by 329
Effects of anti-estrogens on bone in castrated and intact female rats
Jordan, V. C., Phelps, E., & Lindgren, J. U. (1987) · Breast Cancer Research and Treatment · doi:10.1007/bf01806132 · Cited by 324
The Expanding Cosmos of Nuclear Receptor Coactivators
Lonard, D. M., & O'Malley, B. W. (2006) · Cell · doi:10.1016/j.cell.2006.04.021 · Cited by 317
Lim, Y. C., Desta, Z., Flockhart, D. A., & Skaar, T. C. (2005) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-004-0926-7 · Cited by 309
Effect of Estrogen Therapy on Gallbladder Disease
Cirillo, D. J. (2005) · JAMA · doi:10.1001/jama.293.3.330 · Cited by 304
Bazedoxifene Acetate: A Selective Estrogen Receptor Modulator with Improved Selectivity
Komm, B. S., Kharode, Y. P., Bodine, P. V. N., Harris, H. A., Miller, C. P., & Lyttle, C. R. (2005) · Endocrinology · doi:10.1210/en.2005-0030 · Cited by 298
Jordan, V. C., & Brodie, A. M. H. (2007) · Steroids · doi:10.1016/j.steroids.2006.10.009 · Cited by 296
Love, R. R., Newcomb, P. A., Wiebe, D. A., Surawicz, T. S., Jordan, V. C., Carbone, P. P., & DeMets, D. L. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.16.1327 · Cited by 292
Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer
Jordan, V. C. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706399 · Cited by 292
Love, R. R., Wiebe, D. A., Feyzi, J. M., Newcomb, P. A., & Chappell, R. J. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.20.1534 · Cited by 278
McDonald, C. C., Alexander, F. E., Whyte, B. W., Forrest, A. P., & Stewart, H. J. (1995) · BMJ · doi:10.1136/bmj.311.7011.977 · Cited by 276
McInerney, E. M., Weis, K. E., Sun, J., Mosselman, S., & Katzenellenbogen, B. S. (1998) · Endocrinology · doi:10.1210/endo.139.11.6298 · Cited by 269
Hard, G. C., Iatropoulos, M. J., Jordan, K., Radi, L., Kaltenberg, O. P., Imondi, A. R., & Williams, G. M. (1993) · PubMed · Cited by 265
Pignone, M. (2000) · BMJ · doi:10.1136/bmj.321.7267.983 · Cited by 259
Powles, T., Hardy, Jr., Ashley, S., Farrington, G., Cosgrove, D., Davey, J., Dowsett, M., McKinna, J., Nash, A., Sinnett, H., et al. (1989) · British Journal of Cancer · doi:10.1038/bjc.1989.235 · Cited by 246
Comparative Analyses of Mechanistic Differences Among Antiestrogens1
Wijayaratne, A. L., Nagel, S. C., Paige, L. A., Christensen, D. J., Norris, J. D., Fowlkes, D. M., & McDonnell, D. P. (1999) · Endocrinology · doi:10.1210/endo.140.12.7164 · Cited by 244
Siris, E. S., Harris, S. T., Eastell, R., Zanchetta, J. R., Goemaere, S., Diez-Perez, A., Stock, J. L., Song, J., Qu, Y., Kulkarni, P. M., et al. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050509 · Cited by 243
Molecular determinants of tissue selectivity in estrogen receptor modulators
Grese, T. A., Sluka, J. P., Bryant, H. U., Cullinan, G. J., Glasebrook, A. L., Jones, C. D., Matsumoto, K., Palkowitz, A. D., Sato, M., Termine, J. D., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.25.14105 · Cited by 243
Tamoxifen prevents the skeletal effects of ovarian hormone deficiency in rats
Turner, R. T., Wakley, G. K., Hannon, K. S., & Bell, N. H. (1987) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650020513 · Cited by 242
Antagonism of estrogen action with a new benzothiophene derived antiestrogen
Black, L. J., Jones, C. D., & Falcone, J. F. (1983) · Life Sciences · doi:10.1016/0024-3205(83)90935-9 · Cited by 239
Lindsay, R., Gallagher, J. C., Kagan, R., Pickar, J. H., & Constantine, G. (2009) · Fertility and Sterility · doi:10.1016/j.fertnstert.2009.02.093 · Cited by 234
Miller, P. D., Chines, A. A., Christiansen, C., Hoeck, H. C., Kendler, D. L., Lewiecki, E. M., Woodson, G., Levine, A. B., Constantine, G., & Delmas, P. D. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.071206 · Cited by 234
LERNER, L. J., HOLTHAUS, F. J., & THOMPSON, C. R. (1958) · Endocrinology · doi:10.1210/endo-63-3-295 · Cited by 233
TURNER, R. T., WAKLEY, G. K., HANNON, K. S., & BELL, N. H. (1988) · Endocrinology · doi:10.1210/endo-122-3-1146 · Cited by 224
The agonistic-antagonistic properties of clomiphene: A review
Clark, J. H., & Markaverich, B. M. (1981) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(81)90055-3 · Cited by 222
Kraichely, D. M., Sun, J., Katzenellenbogen, J. A., & Katzenellenbogen, B. S. (2000) · Endocrinology · doi:10.1210/endo.141.10.7698 · Cited by 217
Jordan, V. C., & Allen (née Naylor), K. E. (1980) · European Journal of Cancer (1965) · doi:10.1016/0014-2964(80)90156-5 · Cited by 214
Chemoprevention of breast cancer with selective oestrogen-receptor modulators
Jordan, V. C. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2048 · Cited by 206
E3 Ubiquitin Ligases as Cancer Targets and Biomarkers
Sun, Y. (2006) · Neoplasia · doi:10.1593/neo.06376 · Cited by 205
Tamoxifen: Catalyst for the change to targeted therapy
Jordan, V. C. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2007.11.002 · Cited by 199
(2002) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-200211000-00019 · Cited by 196
Hormonal Pathogenesis of Adenocarcinoma of the Breast
Lacassagne, A. (1936) · The American Journal of Cancer · doi:10.1158/ajc.1936.217 · Cited by 194
Kemp, D. C., Fan, P. W., & Stevens, J. C. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.6.694 · Cited by 193
Greenblatt, R. B., Roy, S., & Mahesh, V. B. (1962) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(62)90067-4 · Cited by 190
Survival versus apoptotic 17β‐estradiol effect: Role of ERα and ERβ activated non‐genomic signaling
Acconcia, F., Totta, P., Ogawa, S., Cardillo, I., Inoue, S., Leone, S., Trentalance, A., Muramatsu, M., & Marino, M. (2005) · Journal of Cellular Physiology · doi:10.1002/jcp.20219 · Cited by 182
Hormone replacement therapy and the risk of breast cancer
Narod, S. A. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.110 · Cited by 178
Palkowitz, A. D., Glasebrook, A. L., Thrasher, K. J., Hauser, K. L., Short, L. L., Phillips, D. L., Muehl, B. S., Sato, M., Shetler, P. K., Cullinan, G. J., et al. (1997) · Journal of Medicinal Chemistry · doi:10.1021/jm970167b · Cited by 177
Grese, T. A., Cho, S., Finley, D. R., Godfrey, A. G., Jones, C. D., Lugar, C. W., Martin, M. J., Matsumoto, K., Pennington, L. D., Winter, M. A., et al. (1997) · Journal of Medicinal Chemistry · doi:10.1021/jm9606352 · Cited by 176
Ettinger, B., Black, D. M., Mitlak, B. H., Knickerbocker, R. K., Nickelsen, T., Genant, H. K., Christiansen, C., Delmas, P. D., Zanchetta, J. R., Stakkestad, J., et al. (2000) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-200001000-00021 · Cited by 168
Ke, H. Z., Paralkar, V. M., GRASSER, W. A., Crawford, D. T., Qi, H., Simmons, H. A., Pirie, C. M., Chidsey-Frink, K. L., Owen, T. A., Smock, S. L., et al. (1998) · Endocrinology · doi:10.1210/endo.139.4.5902 · Cited by 161
Safety and Adverse Effects Associated With Raloxifene: Multiple Outcomes of Raloxifene Evaluation
Grady, D., Ettinger, B., Moscarelli, E., Plouffe, L., Sarkar, S., Ciaccia, A., & Cummings, S. (2004) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000137349.79204.b8 · Cited by 159
Transcriptional Regulation by Steroid Receptor Coactivator Phosphorylation
Wu, R., Smith, C. L., & O’Malley, B. W. (2005) · Endocrine Reviews · doi:10.1210/er.2004-0018 · Cited by 159
Effect of Statins on Risk of Coronary Disease: A Meta-analysis of Randomized Controlled Trials
LaRosa, J. C., He, J., & Vupputuri, S. X. (2000) · Survey of Anesthesiology · doi:10.1097/00132586-200012000-00024 · Cited by 157
Comparative analyses of mechanistic differences among antiestrogens.
Wijayaratne, A., Nagel, S., Paige, L. A., Christensen, D., Norris, J., Fowlkes, D., & McDonnell, D. (1999) · Endocrinology · doi:10.1210/en.140.12.5828 · Cited by 157
Clomiphene protects against osteoporosis in the mature ovariectomized rat
Beall, P. T., Misra, L. K., Young, R. L., Spjut, H. J., Evans, H. J., & LeBlanc, A. (1984) · Calcified Tissue International · doi:10.1007/bf02405304 · Cited by 140
Design, Synthesis, and Preclinical Characterization of Novel, Highly Selective Indole Estrogens
Miller, C. P., Collini, M. D., Tran, B. D., Harris, H. A., Kharode, Y. P., Marzolf, J. T., Moran, R. A., Henderson, R. A., Bender, R. H. W., Unwalla, R. J., et al. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm010086m · Cited by 137
de Villiers, T. J., Chines, A. A., Palacios, S., Lips, P. T. A. M., Sawicki, A. Z., LEVINE, A., Codreanu, C., Kelepouris, N., & Brown, J. P. (2010) · Osteoporosis International · doi:10.1007/s00198-010-1302-6 · Cited by 137
LY353381.HCl: A Novel Raloxifene Analog with Improved SERM Potency and Efficacy In Vivo
Sato, M., Turner, C. H., Wang, T., Adrian, M. D., Rowley, E. R., & Bryant, H. U. (1998) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37755-9 · Cited by 136
Rosati, R. L., Jardine, P. D. S., Cameron, K. O., et al. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm980048b · Cited by 135
Suppression of Mouse Mammary Tumorigenesis by Long-Term Tamoxifen Therapy
Jordan, V. C., Lababidi, M. K., & Langan-Fahey, S. M. (1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.7.492 · Cited by 134
Lieberman, M. E., Gorski, J., & Jordan, V. C. (1983) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)32484-0 · Cited by 132
Jordan, V. C., DIX, C. J., Rowsby, L., & Prestwich, G. (1977) · Molecular and Cellular Endocrinology · doi:10.1016/0303-7207(77)90066-1 · Cited by 129
New Synthetic Agent for the Induction of Ovulation: Preliminary Trials in Women
Klopper, A. I., & Hall, M. (1971) · BMJ · doi:10.1136/bmj.1.5741.152 · Cited by 129
Gottardis, M. M., Ricchio, M. E., SATYASWAROOP, P. G., et al. (1990) · PubMed · Cited by 128
Grese, T. A., Pennington, L. D., Sluka, J. P., Adrian, M. D., Cole, H. W., Fuson, T. R., Magee, D. E., Phillips, D. L., Rowley, E. R., Shetler, P. K., et al. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm970688z · Cited by 126
Species-specific pharmacology of antiestrogens: role of metabolism.
Jordan, V. C., & Robinson, S. P. (1987) · PubMed · Cited by 125
Qu, Q., Zheng, H., Dahllund, J., Laine, A. M., Cockcroft, N., Peng, Z., Koskinen, M., Hemminki, K., Kangas, L., Väänänen, K., et al. (2000) · Endocrinology · doi:10.1210/endo.141.2.7342 · Cited by 120
Bazedoxifene/conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal women
Archer, D. F., Lewis, V., Carr, B. R., Olivier, S., & Pickar, J. H. (2009) · Fertility and Sterility · doi:10.1016/j.fertnstert.2009.05.093 · Cited by 118
Bazedoxifene, a selective estrogen receptor modulator
Archer, D. F., Pinkerton, J. V., Utian, W. H., Menegoci, J. C., de Villiers, T. J., Yuen, C. K., Levine, A. B., Chines, A. A., & Constantine, G. D. (2009) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e3181a818db · Cited by 115
Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene
McClung, M. R., Siris, E. S., Cummings, S., Bolognese, M. A., Ettinger, M. P., Moffett, A. H., Emkey, R. D., Day, W. W., Somayaji, V. R., & Lee, A. (2006) · Menopause The Journal of The North American Menopause Society · doi:10.1097/01.gme.0000188736.69617.4f · Cited by 111
Ronkin, S., Northington, R. S., Baracat, E. C., Nunes, M. G., Archer, D. F., Constantine, G. D., & Pickar, J. H. (2005) · Obstetrics and Gynecology · doi:10.1097/01.aog.0000163253.27610.b9 · Cited by 111
Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women
Cummings, S. R., McClung, M. R., Reginster, J., Cox, D., Mitlak, B., Stock, J. L., Amewou-Atisso, M. G., Powles, T. J., Miller, P. D., Zanchetta, J., et al. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.191 · Cited by 110
Rutanen, E., Heikkinen, J. E., Halonen, K., Komi, J., Lammintausta, R. A. S., & Ylikorkala, O. (2003) · Menopause The Journal of The North American Menopause Society · doi:10.1097/01.gme.0000063609.62485.27 · Cited by 108
Selective estrogen receptor modulators as brain therapeutic agents
Arévalo, M., Santos‐Galindo, M., Lagunas, N., Azcoitia, Í., & García‐Segura, L. M. (2010) · Journal of Molecular Endocrinology · doi:10.1677/jme-10-0122 · Cited by 108
Suh, N., Glasebrook, A. L., Palkowitz, A. D., Bryant, H. U., Burris, L. L., Starling, J. J., Pearce, H. L., Williams, C. R., Peer, C. W., Wang, Y., et al. (2001) · PubMed · Cited by 104
THE INDUCTION OF OVULATION BY TAMOXIFEN
Williamson, J. G., & Ellis, J. D. (1973) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.1973.tb11230.x · Cited by 103
Hackshaw, A. K., Roughton, M., Forsyth, S., Monson, K., Reczko, K., Sainsbury, R., & Baum, M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.2933 · Cited by 102
Jain, N. F., Xu, J., Kanojia, R. M., Du, F., Jian-Zhong, G., Pacia, E., Lai, M.-T., Musto, A., Allan, G. F., Reuman, M., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900146e · Cited by 99
Cummings, S. R., Eckert, S., Krueger, K. A., Grady, D. G., Powles, T. J., Cauley, J. A., Norton, L., Nickélsen, T., Bjarnason, N. H., Morrow, M., et al. (2000) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-200002000-00023 · Cited by 92
SERMs: current status and future trends
Morello, K. C., Wurz, G. T., & DeGregorio, M. W. (2002) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(02)00022-7 · Cited by 89
EFFECTS OF TRIPARANOL (MER-29) ON CHOLESTEROL BIOSYNTHESIS AND ON BLOOD STEROL LEVELS IN MAN*
Steinberg, D. H., Avigan, J., & Feigelson, E. B. (1961) · Journal of Clinical Investigation · doi:10.1172/jci104323 · Cited by 85
McMeekin, D. S., Gordon, A. N., Fowler, J. M., Melemed, A. S., Buller, R. E., Burke, T. J., Bloss, J., & Sabbatini, P. J. (2003) · Gynecologic Oncology · doi:10.1016/s0090-8258(03)00203-8 · Cited by 82
Bryant, H. U., Glasebrook, A. L., Yang, N., & Sato, M. (1999) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(98)00147-2 · Cited by 81
Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis
Pinkerton, J. V., Archer, D. F., Utian, W. H., Menegoci, J. C., Levine, A. B., Chines, A. A., & Constantine, G. D. (2009) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e3181a816be · Cited by 81
Komi, J., Lankinen, K. S., H�rk�nen, P. L., DeGregorio, M. W., Voipio, S., Kivinen, S., Tuimala, R. J., ki, T. V., Vihko, K. K., Ylikorkala, O., et al. (2005) · Menopause The Journal of The North American Menopause Society · doi:10.1097/00042192-200512020-00015 · Cited by 78
Effects of ospemifene and raloxifene on biochemical markers of bone turnover in postmenopausal women
Komi, J., Lankinen, K. S., DeGregorio, M. W., Heikkinen, J. E., Saarikoski, S., Tuppurainen, M. T., Halonen, K., Lammintausta, R. A. S., Väänänen, K., Ylikorkala, O., et al. (2006) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-006-0689-9 · Cited by 77
SULFATION OF RALOXIFENE AND 4-HYDROXYTAMOXIFEN BY HUMAN CYTOSOLIC SULFOTRANSFERASES
Falany, J. L., Pilloff, D. E., Leyh, T. S., & Falany, C. N. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.006551 · Cited by 77
Jordan, V. C. (1988) · Cancer Investigation · doi:10.3109/07357908809082124 · Cited by 75
Deshmane, V., Krishnamurthy, S., Melemed, A. S., Peterson, P. M., & Buzdar, A. U. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.5992 · Cited by 75
Estrogen Receptor-α as a Drug Target Candidate for Preventing Lung Inflammation
Vegeto, E., Cuzzocrea, S., Crisafulli, C., Mazzon, E., Sala, A., Krust, A., & Maggi, A. C. (2009) · Endocrinology · doi:10.1210/en.2009-0876 · Cited by 75
Little Molecules with Big Goals
O’Malley, B. W. (2006) · Science · doi:10.1126/science.1132509 · Cited by 74
Mieog, J. S. D., Morden, J. P., Bliss, J. M., Coombes, R. C., & van de Velde, C. J. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70328-x · Cited by 74
Esteva, F. J., & Hortobágyi, G. N. (2005) · The Breast · doi:10.1016/j.breast.2005.08.033 · Cited by 74
Disposition Mechanisms of Raloxifene in the Human Intestinal Caco-2 Model
Jeong, E. J., Lin, H., & Hu, M. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.063925 · Cited by 72
Cataracts produced by triparanol. (MER-29).
Kirby, T. J. (1967) · PubMed · Cited by 71
Komi, J., Heikkinen, J. E., Rutanen, M., Halonen, K., Lammintausta, R. A. S., & Ylikorkala, O. (2004) · Gynecological Endocrinology · doi:10.1080/09513590410001672197 · Cited by 70
Qu, Q., H�rk�nen, P. L., & Väänänen, H. K. (1999) · Journal of Cellular Biochemistry · Cited by 63
Ivanova, M. M., Mazhawidza, W., Dougherty, S. M., Minna, J. D., & Klinge, C. M. (2009) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2009.01.021 · Cited by 62
Namba, R., Young, L. J. T., Maglione, J. E., McGoldrick, E. T., Liu, S., Wurz, G. T., DeGregorio, M. W., Borowsky, A. D., MacLeod, C. L., Cardiff, R. D., et al. (2005) · Breast Cancer Research · doi:10.1186/bcr1317 · Cited by 61
Lindsay, R. S., Gallagher, J. C., Kagan, R., Pickar, J. H., & Constantine, G. D. (2009) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000367517.26041.93 · Cited by 59
Liby, K. T., Rendi, M. H., Suh, N., Royce, D. B., Risingsong, R., Williams, C. R., Lamph, W. W., Labrie, F., Krajewski, S., Xu, X., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1119 · Cited by 59
Gennari, L., Merlotti, D., Martini, G., & Nuti, R. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.9.1091 · Cited by 59
Voipio, S., Komi, J., Kangas, L., Halonen, K., DeGregorio, M. W., & Erkkola, R. (2002) · Maturitas · doi:10.1016/s0378-5122(02)00206-2 · Cited by 58
Fabian, C., Kimler, B., Anderson, J., Tawfik, O., Mayo, M., Burak, W., O'Shaughnessy, J., Albain, K., Hyams, D., Budd, G., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0171 · Cited by 58
Evaluation of the major metabolites of raloxifene as modulators of tissue selectivity
Dodge, J. A., Lugar, C. W., Cho, S., Short, L. L., Sato, M., Yang, N., Spangle, L. A., Martin, M. J., Phillips, D. L., Glasebrook, A. L., et al. (1997) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(97)00008-3 · Cited by 55
Ospemifene inhibits the growth of dimethylbenzanthracene-induced mammary tumors in Sencar mice
Wurz, G. T., Read, K. C., Marchisano-Karpman, C., Gregg, J. P., Beckett, L. A., Yu, Q., & DeGregorio, M. W. (2005) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2005.06.027 · Cited by 53
Effects of Raloxifene on Cardiovascular Events and Breast Cancer in Postmenopausal Women
Barrett‐Connor, E., Mosca, L. J., Collins, P. D., Geiger, M. J., Grady, D. G., Kornitzer, M., McNabb, M. A., & WENGER, N. K. (2006) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000248825.32323.b3 · Cited by 51
Jain, N. F., Kanojia, R. M., Xu, J., Jian-Zhong, G., Pacia, E., Lai, M.-T., Du, F., Musto, A., Allan, G. F., Hahn, et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060353u · Cited by 51
Hz, K. (1998) · Endocrinology · doi:10.1210/en.139.4.2068 · Cited by 48
Ylikorkala, O., Cacciatore, B., Halonen, K., Lassila, R., Lammintausta, R. A. S., Rutanen, E., Heikkinen, J. E., & Komi, J. (2003) · Menopause The Journal of The North American Menopause Society · doi:10.1097/01.gme.0000063566.84134.98 · Cited by 46
Sato, M., Zeng, G. Q., Rowley, E. R., & Turner, C. H. (1998) · Endocrinology · doi:10.1210/endo.139.11.6307 · Cited by 46
Li, Y., Bryant, H. U., Zeng, Q., Palkowitz, A. D., Jee, W. S. S., Turner, C. H., & Sato, M. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.12.2256 · Cited by 46
Gennari, L. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903127241 · Cited by 42
(2007) · Breast Diseases A Year Book Quarterly · doi:10.1016/s1043-321x(07)80084-1 · Cited by 39
Genotoxic effects of the novel mixed antiestrogen FC-1271a in comparison to tamoxifen and toremifene
Hellmann‐Blumberg, U., Taras, T. L., Wurz, G. T., & DeGregorio, M. W. (2000) · Breast Cancer Research and Treatment · doi:10.1023/a:1006311214152 · Cited by 37
Exemestane for Breast-Cancer Prevention in Postmenopausal Women
Litton, J. K. (2012) · Breast Diseases A Year Book Quarterly · doi:10.1016/j.breastdis.2012.06.008 · Cited by 37
Watanabe, N., Ikeno, A., Minato, H., Nakagawa, H., Kohayakawa, C., & Tsuji, J. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm034134+ · Cited by 36
Lasofoxitene: A new type of selective estrogen receptor modulator for the treatment of osteoporosis
Gennari, L. (2006) · Drugs of today · doi:10.1358/dot.2006.42.6.973583 · Cited by 32
1–2 Effects of Raloxifene on Cardiovascular Events and Breast Cancer in Postmenopausal Women
Bevers, T. B. (2007) · Breast Diseases A Year Book Quarterly · doi:10.1016/s1043-321x(07)80007-5 · Cited by 31
Arzoxifene: the development and clinical outcome of an ideal SERM
Münster, P. N. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.3.317 · Cited by 30
Lasofoxifene in Postmenopausal Women With Osteoporosis
Cummings, S. R., Ensrud, K. E., Delmas, P. D., LaCroix, A. Z., Vukičević, S., Reid, D. M., Goldstein, S. R., Sriram, U., Lee, A., Thompson, J. R., et al. (2010) · Obstetrical & Gynecological Survey · doi:10.1097/ogx.0b013e3181e5f28b · Cited by 25
Vogel, V. G. (2007) · Women s Health · doi:10.2217/17455057.3.2.139 · Cited by 22
Not all SERMs are created equal
Goldstein, S. R. (2006) · Menopause The Journal of The North American Menopause Society · doi:10.1097/01.gme.0000222332.31101.42 · Cited by 19
The effect of the new SERM arzoxifene on growth and gene expression in MCF-7 breast cancer cells
Freddie, C. T., Larsen, S. S., Bartholomæussen, M., et al. (2004) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2004.02.003 · Cited by 19
Kendler, D. L., Palacios, S., Cox, D. A., Stock, J. L., Alam, J., Dowsett, S. A., & Zanchetta, J. (2011) · Osteoporosis International · doi:10.1007/s00198-011-1587-0 · Cited by 18
Pinkerton, J. V., & Stovall, D. W. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.532487 · Cited by 15
Structure-Based Approach for the Discovery of Novel Selective Estrogen Receptor Modulators
Rosano, C., Stec‐Martyna, E., Lappano, R., & Maggiolini, M. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711795029645 · Cited by 15
Prakash, C., Johnson, K. A., Schroeder, C. M., & Potchoiba, M. J. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.021808 · Cited by 15
Gruber, C., & Gruber, D. M. (2004) · PubMed · Cited by 15
Villiers, T. D., Kendler, D. L., Chines, A. A., Lips, P. T. A. M., Kaufman, J., Levine, A., Mairon, N., Codreanu, C., Felsenberg, D., & Brown, J. P. (2010) · Bone · doi:10.1016/j.bone.2010.01.039 · Cited by 13
Ronkin, S. (2005) · Obstetrics and Gynecology · doi:10.1097/01.aog.0000186254.52346.aa · Cited by 13
INDUCTION OF OVULATION WITH MRL/41. PRELIMINARY REPORT
Greenblatt, R. B., Barfield, W. E., Jungck, E. C., & RAY, A. W. (1962) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-196204000-00027 · Cited by 10
Qu, Q., Härkönen, P. L., & Väänänen, H. K. (1999) · Journal of Cellular Biochemistry · Cited by 6
Not all selective estrogen response modulators are created equal: update on lasofoxifene
Goldstein, S. R. (2006) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2006.00681.x · Cited by 5
Long term survivors of childhood brain cancer have an increased risk for cardiovascular disease
(2000) · Pure Amsterdam UMC · doi:10.1002/(sici)1097-0142(20000501)88:9
Cited by
Palbociclib and letrozole in advanced breast cancer
Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S.-A., Gelmon, K., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607303 · Cited by 3,007
Why 90% of clinical drug development fails and how to improve it?
Sun, D., Gao, W., Hu, H., & Zhou, S. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.02.002 · Cited by 1,763
Estrogen receptor signaling mechanisms
(2019) · Advances in Protein Chemistry and Structural Biology · doi:10.1016/bs.apcsb.2019.01.001 · Cited by 988
Kenkre, J., & Bassett, J. (2018) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1177/0004563218759371 · Cited by 693
The neuroprotective actions of oestradiol and oestrogen receptors
Arevalo, M.-A., Azcoitia, I., & Garcia-Segura, L. M. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3856 · Cited by 480
Metadata
- Authors
- Y. Maximov, P., M. Lee, T., & Craig Jordan, V.
- Venue
- Current Clinical Pharmacology
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2013-03-01
- Volume
- 8
- Issue
- 2
- Pages
- 135-155
- ISSN
- 1574-8847 (ISSN-L)
- OpenAlex
- W2098505104
- Cited by
- 376
- References
- 194
- FWCI
- 18.82
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.